Use of Nucleoside (Tide) Analogues in Patients with Hepatitis B-Related Acute Liver Failure
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background and Aims
The efficacy of nucleoside(tide) analogues (NA) in the treatment of acute liver failure due to hepatitis B virus (HBV-ALF) remains controversial. We determined retrospectively the impact of NAs in a large cohort of patients with HBV-ALF.
The US Acute Liver Failure Study Group, a 23-site registry, prospectively enrolled 1,413 patients with ALF with different etiologies between 1998 and 2008. Of those, 105 patients were identified as HBV-ALF patients, of whom we excluded those without data on NA use or with co-infection with hepatitis C, leaving 85 patients, 43 of whom had received NA treatment. HBV-DNA on admission was quantified by real time polymerase chain reaction.
The treated and untreated groups were similar in most respects but differed significantly in regard to higher aminotransferase and bilirubin levels and hepatic coma grades, all being observed in the untreated group. Median duration of NA treatment was 6 days (range, 1–21 days). Overall survival in the NA treated and untreated groups were 61 and 64%, respectively (P = 0.72). Rates of transplant-free survival were 21 and 36% in the treated and untreated groups, respectively (P = 0.42). Multivariate analysis revealed that not using a NA [odds ratio (OR) 4.4, 95% CI 1.1–18.1, P = 0.041], hepatic coma grade I or II [OR 14.4, 95% CI 3.3–62.8, P < 0.001] and prothrombin time (PT) [OR 0.59, 95% CI 0.39–0.89, P = 0.012] were predictors of improved transplant-free survival.
Patients who are admitted with established HBV-ALF do not appear to benefit from viral suppression using nucleoside(tide) analogues presumably because of rapid disease evolution and short treatment duration. Despite the lack of benefit, NAs should still be given to transplantation candidates since viral suppression prevents recurrence after grafting.
- Lee WM. Acute liver failure. N Engl J Med. 1993;329:1862–1872. CrossRef
- Scotto J, Opolon P, Eteve J, Vergoz D, Thomas M, Caroli J. Liver biopsy and prognosis in acute liver failure. Gut. 1973;14:927–933. CrossRef
- Lee HC. Acute liver failure related to hepatitis B virus. Hepatol Res. 2008;38:S9–S13. CrossRef
- Wai CT, Fontana RJ, Polson J, et al. Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States. J Viral Hepat. 2005;12:192–198. CrossRef
- Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–662. CrossRef
- Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359:1486–1500. CrossRef
- Kumar M, Satapathy S, Monga R, et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology. 2007;45:97–101. CrossRef
- Bernuau J, Goudeau A, Poynard T, et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology. 1986;6:648–651. CrossRef
- Woolf IL, El Sheikh N, Cullens H, et al. Enhanced HBsAb production in pathogenesis of fulminant viral hepatitis type B. Br Med J. 1976;2:669–671. CrossRef
- Dao DY, Hynan LS, Yuan HJ, et al. Two distinct subtypes of hepatitis B virus-related acute liver failure are separable by quantitative serum IgM anti-HBc and HBV DNA levels. Hepatology. Epub. 10/10/2011.
- Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137:856–864. CrossRef
- Reshef R, Sbeit W, Tur-Kaspa R. Lamivudine in the treatment of acute hepatitis B. N Engl J Med. 2000;343:1123–1124. CrossRef
- Schmilovitz-Weiss H, Ben-Ari Z, Sikuler E, et al. Lamivudine treatment for acute severe hepatitis B: a pilot study. Liver Int. 2004;24:547–551. CrossRef
- Tillmann HL, Hadem J, Leifeld L, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat. 2006;13:256–263. CrossRef
- Miyake Y, Iwasaki Y, Takaki A, et al. Lamivudine treatment improves the prognosis of fulminant hepatitis B. Intern Med. 2008;47:1293–1299. CrossRef
- Chisari FV. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol. 2000;156:1117–1132. CrossRef
- Webster GJ, Reignat S, Maini MK, et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology. 2000;32:1117–1124. CrossRef
- Tsubota A, Arase Y, Suzuki Y, et al. Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol. 2005;20:426–432. CrossRef
- Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med. 2009;150:104–110.
- Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341:1256–1263. CrossRef
- Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 1995;333:1657–1661. CrossRef
- Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148:519–528.
- Lee WC, Wu MJ, Cheng CH, Chen CH, Shu KH, Lian JD. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients. Am J Kidney Dis. 2001;38:1074–1081. CrossRef
- Angus PW, Patterson SJ. Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/antiviral regimen? Liver Transpl. 2008;14:S15–S22. CrossRef
- Use of Nucleoside (Tide) Analogues in Patients with Hepatitis B-Related Acute Liver Failure
Digestive Diseases and Sciences
Volume 57, Issue 5 , pp 1349-1357
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Liver transplantation
- Severe viral hepatitis
- Industry Sectors
- Author Affiliations
- 1. Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
- 2. Makerere University Medical School, Kampala, Uganda
- 3. Department of Clinical Sciences (Biostatistics), University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
- 4. Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA
- 5. Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX, 75390-8887, USA